CALBIOCHEM -- RIFAMPICIN, 557303 ======================================================= MSDS Safety Information ======================================================= FSC: 6505 MSDS Date: 06/07/1999 MSDS Num: CJSPJ LIIN: 00N092493 Product ID: RIFAMPICIN, 557303 MFN: 01 Responsible Party Cage: 29089 Name: CALBIOCHEM Box: 12087 City: LA JOLLA CA 92039-2087 Info Phone Number: 800-854-3417 Emergency Phone Number: (800)424-9300 Chemtrec IND/Phone: (800)424-9300 Review Ind: Y Published: Y ======================================================= Contractor Summary ======================================================= Cage: 29089 Name: CALBIOCHEM Box: 12087 City: LA JOLLA CA 92039-2087 Phone: 619-450-5558; 800-854-3417 ======================================================= Item Description Information ======================================================= ======================================================= Ingredients ======================================================= Cas: 13292-46-1 RTECS #: VJ7000000 Name: RIFAMPICIN LD50: (ORAL, RAT) 1570 MG/KG ======================================================= Health Hazards Data ======================================================= LD50 LC50 Mixture: SEE INGREDIENT AND TOXICOLOGICAL INFO Route Of Entry Inds - Inhalation: YES Skin: YES Ingestion: YES Carcinogenicity Inds - NTP: NO IARC: NO OSHA: NO Effects of Exposure: ACUTE EFFECTS: MAY BE HARMFUL BY INGESTION, INHALATION OR ABSORPTION THROUGH SKIN. MATERIAL MAY CAUSE IRRITATION TO THE EYES, SKIN, MUCOUS MEMBRANES, AND THE UPPER RESPIRATORY TRACT. EXPOSURE TO MATER IAL MAY CAUSE THE FOLLOWING: NAUSEA, VOMITING, ABDOMINAL CRAMPS, DIARRHEA, HEADACHE, FATIGUE, DROWSINESS, DIZZINESS, FAILURE OF MUSCLE COORDINATION, CONFUSION, GENERALIZED NUMBNESS, PAIN IN THE EXTREM ITIES, MUSCLE WEAKNESS, DECREASE IN THE NUMBER OF BLOOD PLATELETS, REDUCTION IN THE NUMBER OF LEUKOCYTES IN THE BLOOD, ANEMIA, FEVER, SKIN RASH, RENAL INSUFFICIENCY, ACUTE RENAL FAILURE AND JAUNDICE. (EFFECTS OF OVEREXPOSURE) Signs And Symptions Of Overexposure: HEALTH HAZARDS: CHRONIC EFFECTS: THERE IS LIMITED EVIDENCE THAT RIFAMPICIN IS TERATOGENIC AND TUMORIGENIC IN LABORATORY ANIMALS. THERE IS ALSO LIMITED EVIDENCE THAT RIFAMPICIN IS MUTAGENIC IN LABORATO RY CELL CULTURES. UNTIL FURTHER TESTING HAS BEEN DONE, IT SHOULD BE TREATED AS A POSSIBLE TERATOGEN, MUTAGEN AND TUMORIGEN IN HUMANS. First Aid: SKIN: IN CASES OF SKIN CONTACT, WASH IMMED W/COPIOUS AMOUNTS OF WATER FOR AT LEAST 15 MINUTES. REMOVE CONTAMINATED CLOTHING AND SHOES AND WASH BEFORE WEARING. CONSULT MD. EYES: IN CASES OF EYE CONTACT , FLUSH IMMED W/COPIOUS AMOUNTS OF WATER FOR AT LEAST 15 MINUTES. ASSURE ADEQUATE FLUSHING BY SEPARATING EYELIDS W/FINGERS. CONSULT MD. INHAL: IN CASES OF INHALATION, REMOVE TO FRESH AIR AND MONITOR B REATHING. IF BREATHING BECOMES DIFFICULT, GIVE OXYGEN AND CONSULT MD. IF BREATHING STOPS, GIVE ARTIFICIAL RESPIRATION AND CONSULT MD. INGEST: IN CASES OF INGESTION, WASH MOUTH OUT W/WATER AND CONSULT LOCAL POISON CENTER AND MD. ======================================================= Handling and Disposal ======================================================= Spill Release Procedures: EVACUATE AREA. WEAR A NIOSH APPROVED RESPIRATOR, CHEMICAL SAFETY GOGGLES, RUBBER BOOTS AND HEAVY RUBBER GLOVES. SWEEP UP AND PLACE IN A SUITABLE CONTAINER. AVOID RAISING DUST. HOLD FOR APPROPRIATE DIS POSAL. WASH SPILL SITE AND VENTILATE AREA AFTER MATERIAL PICKUP IS COMPLETE. Waste Disposal Methods: COUNTRY, FEDERAL, STATE & LOCAL REGS ARE VAIRED & CHANGE FREQUENTLY. FOR THIS REASON, WE RECOMMEND THAT YOU CONT YOUR LOCAL DEPARTMENT OF HEALTH SERVICES FOR INFO ON THE DISPOSAL OF THIS PROD/ARRANGE FOR DISPOSAL BY A LICENSED DISPOSAL COMPANY. DISPOSE OF IN ACCORDANCE WITH FEDERAL, STATE AND LOCAL REGULATIONS (FP N). Handling And Storage Precautions: STORE IN A TIGHTLY CLOSED CONTAINER IN A COOL, DRY PLACE (+20C). MATERIAL IS HARMFUL AND AN IRRITANT. POSSIBLE TERATOGEN, MUTAGEN AND TUMORIGEN. AVOID CONTACT WITH MATERIAL. AVOID PROLONGED OR REPEATE D EXPOSURE. Other Precautions: LAB SHOULD BE EQUIPPED WITH A SAFETY SHOWER AND AN EYE WASH STATION. WASH THOROUGHLY AFTER HANDLING MATERIAL. ======================================================= Fire and Explosion Hazard Information ======================================================= Extinguishing Media: DRY CHEMICAL POWDER, CARBON DIOXIDE, WATER SPRAY, ALCOHOL OR POLYMER FOAM. Fire Fighting Procedures: USE NIOSH APPROVED SCBA AND FULL PROTECTIVE EQUIPMENT (FP N) TO PREVENT CONTACT WITH SKIN AND EYES. Unusual Fire/Explosion Hazard: UPON THERMAL DECOMPOSITION, IT MAY EMIT TOXIC GASES. ======================================================= Control Measures ======================================================= Respiratory Protection: USE A NIOSH APPROVED RESPIRATOR. Ventilation: HANDLE IN A CHEMICAL FUME HOOD. Protective Gloves: CHEMICAL RESISTANT GLOVES. Eye Protection: ANSI APPROVED CHEMICAL WORKERS GOGGLES (FP N). Other Protective Equipment: ANSI APPROVED EYE WASH AND DELUGE SHOWER (FP N). WEAR SUITABLE PROTECTIVE CLOTHING. Supplemental Safety and Health: PHYSICAL DATA: SOLUBILITY: SOLUBLE IN DMSO. RIFAMPICIN: MOLECULAR WEIGHT: 823.0; MOLECULAR FORMULA: C*43H*58N*4O*12. ======================================================= Physical/Chemical Properties ======================================================= Melt/Freeze Pt: >183.C, 361.4F Appearance and Odor: RED SOLID. ======================================================= Reactivity Data ======================================================= Stability Indicator: YES Stability Condition To Avoid: N/A. STABLE UNDER NORMAL HANDLING PROCEDURES. Materials To Avoid: N/A. Hazardous Decomposition Products: UPON THERMAL DECOMPOSITION, MAY EMIT TOXIC GASES INCLUDING CARBON MONOXIDE, CARBON DIOXIDE AND NITROGEN OXIDE. Hazardous Polymerization Indicator: NO ======================================================= Toxicological Information ======================================================= Toxicological Information: RTECS NUMBER: VJ7000000. TOX DATA & REFERENCES: ORL; HMN; TDLO: 180 MG/KG CONJUNCTIVE IRRIT; DERM 1977. BRITISH MEDICAL JOURNAL. 2, 1189. ORL; MAN; TDLO: 13 MG/KG/2D TOX EFTS ON SENSE ORGANS 1976. BRI TISH MEDICAL JOURNAL. 1, 199. ORL; WMN; TDLO: 504 MG/KG MUSC WEAK; DYSPNEA; APLASTIC ANEMIA 1989. AMERICAN JOURNAL OF MEDICINE. 87, 459. ORL; WMN; TLDO: 315 MG/KG/5W-I DERM 1987. JOURNAL OF THE AMERIC AN ACADEMY OF DERMATOLOGY. 17, 303. ORL; MAN; LDLO: 857 MG/KG NAUS; VOMIT; DERM 1978. JAMA, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 240, 2283. ORL; RAT; LD50: 1570 MG/KG 1970. JAPANESE JOURNAL OF ANTIBIOTICS. 23, 242. (OTHER INFO) ======================================================= Ecological Information ======================================================= Ecological: NO INFORMATION AVAILABLE. OTHER INFO: CHEMOTHERAPIA (BASEL, 1954-70). 16, 316. REPRO EFTS & REFERENCES: ORL; RAT; DOSE: 1400 MG/KG CRANIOFACIAL & MUSCULOSKELETAL SYS DEVELOPMENTAL ABNORMS 1969. COMPT ES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCES, SERIE D: SCIENCES NATURELLES. 269, 2147. ORL; RAT; DOSE: 3200 MG/KG TOX EFTS ON LITTER SIZE 1969. COMPTES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCE S, SERIE D: SCIENCES NATURELLES. 269, 2147. ORL; RAT; DOSE: 4 G/KG OTHER DEVELOPMENTAL ABNORMS 1970. ANTIBIOTICA ET CHEMOTHERAPIA (BASEL, 1954-70). 16, 316. ORL; RAT; DOSE: 800 MG/KG POST-IMPLANTATION MORTALITY; UROGENITAL (TRANSPORT INFO) ======================================================= MSDS Transport Information ======================================================= Transport Information: UN NUMBER: N/A. PROPER SHIPPING NAME: N/A. IATA CLASS: N/A. IATA PACKING GROUP: N/A. ECOLOGICAL INFO: & CNS DEVELOPMENTAL ABNORMS 1991. PROBLEMY TUBERKULEZA. PROBLEMS OF TUBERCULOSIS. 69(2), 67. ORL; MUS; DOSE: 2200 MG/KG CRANIOFACIAL & MUSCULOSKELETAL SYS DEVELOPMENTAL ABNORMS 1969. COMPTES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCES, SERIE D: SCIENCES NATURELLES. 269, 2147. ORL; RBT; DOSE: 260 0 MG/KG POST-IMPLANTATION MORTALITY 1970. ANTIBIOTICA ET CHEMOTHERAPIA (BASEL, 1954-70). 16, 316. GENETIC DATA & REFERENCES: HLA; HMN; DOSE: 250 MG/L DNA INHIBITION 1984. INDIAN JOURNAL OF EXPERIMENTA L BIOLOGY. (SARA REG INFO) ======================================================= Regulatory Information ======================================================= Sara Title III Information: N/P. TRANSPORT INFO: 22, 350. LYM; HMN; DOSE: 100 MG/L DNA INHIBITION 1974. BIOCHEMICAL & BIOPHYSICAL RESEARCH COMMUNICATIONS. 60, 96. LYM; HMN; DOSE: 25 MG/L CYTOGENETIC ANALYSIS 1977. MUTATION RESEA RCH. 48, 215. OTH; HMN; DOSE: 78 MG/L CYTOGENETIC ANLAYSIS 1974. EXPERIENTIA. 30, 484. AST; MUS; DOSE: 5 MG/KG HOST-MEDIATED ASSAY 1984. MUTATION RESEARCH. 141, 171. HLA; HMN; DOSE: 150 MG/L OTHER MUT ATION TEST SYS 1974. EXPERIENTIA. 30, 484. HLA; HMN; DOSE: 250 MG/L OTHER MUTATION TEST SYS 1984. INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY. 22, 350. OTH; HMN; DOSE: 150 MG/L OTHER MUTATION TEST SYS 1974 . EXPERIENTIA. 30, 484. (STATE REG INFO) Federal Regulatory Information: REGULATORY INFO: XN, XI. RISK PHRASES - R20/21/22: HARMFUL BY INHALATION, IN CONTACT WITH SKIN AND IF SWALLOWED. R36/37/38: IRRITATING TO EYES, RESPIRATORY SYSTEM AND SKIN. R40: POSSIBLE RISK OF IRREV ERSIBLE EFFECTS. SAFETY PHRASES - S22: DO NOT BREATHE DUST. S24/25: AVOID CONTACT WITH SKIN AND EYES. S26: IN CASE OF CONTACT WITH EYES, RINSE IMMEDIATELY WITH PLENTY OF WATER AND SEEK MEDICAL ADVICE. S36/37/39: WEAR SUITABLE PROTECTIVE CLOTHING, GLOVES AND EYE/FACE PROTECTION. S45: IN CASE OF ACCID ENT OR IF YOU FEEL UNWELL, SEEK MEDICAL ADVICE IMMEDIATELY. State Regulatory Information: N/P. SARA REG INFO: TURORIGENIC DATA & REFERENCES: ORL; MUS; DOSE: 8400 MG/KG/60W-C NEOPLASTIC BY RTECS CRITERIA; LIVER TUMORS 1978. TOX & APPLIED PHARMACOLOGY. 43, 293. REVIEWS: IARC CANCER REVIEW: A NIMAL LIMITED EVID REFERENCE 1980. IARC MONO. 24, 243. IARC CANCER REVIEW: GRP 3 REFERENCE 1987. IARC MONO, SUPP. 7, 56. IARC CANCER REVIEW: HUMAN NO ADEQ DATA REFERENCE 1980. IARC MONO. 24, 243. TOX REVIEW REFERENCE 1973. MUENCHENER MEDICINISCHE WOCHENSCHRIFT 115, 1685. TOX REVIEW REFERENCE 1980. L ANCET. 2, 1285. REFER TO RTECS FOR DEFINITION OF ABBREVIATIONS USED & FOR ADDNL INFO. THIS REPORT CNTNS ONLY SELECTED INFO FROM RTECS. ======================================================= Other Information ======================================================= Other Information: AVOID CONTACT W/MATL. AVOID PRLNGD/RPTD EXPOS. WASH THOROUGHLY AFTER HNDLG. MATL SHOULD ONLY BE HANDLED BY QUALIFIED, EXPERIENCED PROFESSIONALS. THE ABOVE INFO IS BELIEVED TO BE CORRECT BUT DOES NOT P URPORT TO BE ALL INCLUSIVE & SHALL BE USED ONLY AS A GUIDE FOR EXPERIENCED PERS. TOXICOLOGICAL INFO: ORL; MUS; LD50: 500 MG/KG 1969. COMPTES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCES, SERIE D: SCI ENCES NATURELLES. 269, 2147. ORL; RBT; LD50: 2120 MG/KG 1970. ANTIBIOTICA ET CHEMOTHERAPIA (BASEL, 1954-70). 16, 316. IPR; MUS; LD50: 416 MG/KG 1967. CHEMOTHERAPIA. 12, 155. IVN; MUS; LD50: 260 MG/KG 1970. ANTIBIOTICA ET (ECOLOGICAL INFO) ======================================================= HAZCOM Label ======================================================= Product ID: RIFAMPICIN, 557303 Cage: 29089 Company Name: CALBIOCHEM PO Box: 12087 City: LA JOLLA CA Zipcode: 92039-2087 Health Emergency Phone: (800)424-9300 Label Required IND: Y Date Of Label Review: 11/10/1999 Status Code: A Origination Code: F Chronic Hazard IND: Y Eye Protection IND: YES Skin Protection IND: YES Signal Word: WARNING Respiratory Protection IND: YES Health Hazard: Moderate Contact Hazard: Moderate Fire Hazard: None Reactivity Hazard: None Hazard And Precautions: UPON THERMAL DECOMPOSITION, IT MAY EMIT TOXIC GASES. ACUTE EFFECTS: MAY BE HARMFUL BY INGEST, INHAL/ABSORPTION THROUGH SKIN. MATL MAY CAUSE IRRIT TO THE EYES, SKIN, MUCOUS MEMBS, & THE UPPER RESP TRAC T. EXPOS TO MATL MAY CAUSE THE FOLLOWING: NAUS, VOMIT, ABDOMINAL CRAMPS, DIARR, HDCH, FATG, DROW, DIZZ, FAILURE OF MUSCLE COORD, CONFUSION, GENERALIZED NUMBNESS, PAIN IN THE EXTREMITIES, MUSCLE WEAKNE SS, DECREASE IN THE NUMBER OF BLOOD PLATELETS, REDUCTION IN NUMBER OF LEUKOCYTES IN THE BLOOD, ANEMIA, FEVER, SKIN RASH, RENAL INSUFFICIENCY, ACUTE RENAL FAILURE & JAUNDICE. CHRONIC: POSS TERATOGEN,T UMORIGEN & MUTAGEN. ======================================================= Disclaimer (provided with this information by the compiling agencies): This information is formulated for use by elements of the Department of Defense. The United States of America in no manner whatsoever expressly or implied warrants, states, or intends said information to have any application, use or viability by or to any person or persons outside the Department of Defense nor any person or persons contracting with any instrumentality of the United States of America and disclaims all liability for such use. Any person utilizing this instruction who is not a military or civilian employee of the United States of America should seek competent professional advice to verify and assume responsibility for the suitability of this information to their particular situation regardless of similarity to a corresponding Department of Defense or other government situation.